# RADIATION AND DRUG EFFECTS IN MAMMALIAN CELLS

> **NIH NIH R01** · UNIVERSITY OF TEXAS MED BR GALVESTON · 1991 · $219,764

## Abstract

The long term objectives of the research described in this competing
continuation application remain the clarification of the relationship
between the development of resistance to chemotherapeutic agents,
specifically Adriamycin, and change in radiation response; to determine
the role of cell membrane in the expression of radiation damage by the
use of drug-resistant membrane variants; and to study the damage
interactions between chemotherapeutic agents and radiation in drug-
resistant cell populations.  The working hypothesis is that the cell
membrane represents an important structure with regard to the
cytotoxicity of certain chemotherapeutic agents, particularly
Adriamycin, and that the interaction between Adriamycin and radiation
damage occurs predominantly in that structure.  Chinese hamster lung
fibroblasts (V-79) and their Adriamycin-resistant variants will be used
throughout these studies.  Radiation, Adriamycin, and combination
survival curves will be determined.  Cell membrane preparations will be
isolated form both sensitive and Adriamycin-resistant cells and a
partially purified preparation of a glycoprotein of 170,000 daltons
fused to sensitive cells.  Adriamycin, radiation, and
Adriamycin/radiation survival responses will be determined in the fusion
products.  The presence or absence of the high molecular weight
glycoprotein will be determined in the fusion products.  The presence or
absence of the high molecular weight glycoprotein will be determined
with 1-dimensional electrophoretic techniques.  Intracellular and
membrane-bound Adriamycin will be determined fluorometrically utilizing
the fluorescence of the chromphore.

The time-course of gp170 persistence in fusion products will be
determined by radiation and/or Adriamycin survival responses as a
function of time after fusion.

In addition to single dose radiation responses, studies will be designed
to test the capacity of Adriamycin-resistant cells and fusion products,
as described above, to repair sub-lethal or potentially lethal radiation
injury.  If the long term objectives of the research described in this
proposal are realized, the data may provide important information
relative to the mechanisms of the development of resistance to
chemotherapeutic agents, the radiation response of such resistant cells,
and the possible genetic control of these mechanisms.  Such information
may have important implications in the treatment of patients who have
failed chemotherapy and the prediction of subsequent radiation response
of drug-resistant tumor cells.

## Key facts

- **NIH application ID:** 3171997
- **Project number:** 5R01CA034269-08
- **Recipient organization:** UNIVERSITY OF TEXAS MED BR GALVESTON
- **SAM.gov UEI:** MSPWVMXXMN76
- **Principal Investigator:** JAMES A BELLI
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1991
- **Award amount:** $219,764
- **Award type:** 5
- **Project period:** 1982-07-01 → 1992-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3171997

## Citation

> US National Institutes of Health, RePORTER application 3171997, RADIATION AND DRUG EFFECTS IN MAMMALIAN CELLS (5R01CA034269-08). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3171997. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*